Targovax ASA: First quarter 2019 results
Oslo, Norway, 9 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2019 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE FIRST QUARTER 2019 · The first patient was treated in the dose expansion cohort of the ONCOS-102 trial in checkpoint inhibitor refractory advanced melanoma · Finalized the first development stage for new viruses, filed patents on three viruses · The